Global Ketorolac Injection Market Size By Type (15mg/ml, 30mg/ml), By Application (Hospital, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Ketorolac Injection Market was valued at USD 445 million in 2023 and is projected to reach USD 679 million by 2031, growing at a CAGR of 5.4% during the forecast period from 2023 to 2031. Ketorolac injection, a potent non-steroidal anti-inflammatory drug (NSAID), is widely utilized for short-term management of moderate to severe pain, often post-surgery. Market growth is being driven by the increasing volume of surgical procedures, the shift toward non-opioid pain management strategies, and growing awareness of the adverse effects of long-term opioid use.

Drivers:

1. Rising Surgical Volume:

The global increase in orthopedic, dental, gynecological, and other surgical procedures significantly contributes to the rising demand for ketorolac injections as an effective post-operative analgesic.

2. Preference for Non-Opioid Analgesics:

Growing concerns over opioid dependency and regulations surrounding narcotic prescriptions have led to a shift towards NSAIDs like ketorolac for pain relief.

3. Increasing Geriatric Population:

With age-related surgeries on the rise, especially orthopedic interventions, the demand for efficient injectable analgesics like ketorolac is surging.

Restraints:

1. Risk of Adverse Effects:

Long-term or inappropriate use of ketorolac injection may lead to gastrointestinal, renal, or cardiovascular complications, limiting its prescription in certain patient populations.

2. Regulatory Restrictions:

Due to potential side effects, many countries have placed strict guidelines on ketorolac’s dosage and duration, potentially impacting broader market penetration.

Opportunity:

1. Expanding Application in Ambulatory Surgical Centers:

The rapid growth of outpatient surgeries and ambulatory centers is driving demand for fast-acting and effective analgesics like ketorolac injections.

2. Emerging Markets Expansion:

Developing regions in Asia-Pacific, Latin America, and Africa are experiencing healthcare infrastructure growth, offering significant untapped potential for market players.

3. Reformulation and Combination Therapies:

Innovation in ketorolac formulations, including combination with local anesthetics and prolonged-release formats, offers future growth avenues.

Market by System Type Insights:

By formulation type, the 30 mg/mL concentration segment held the largest share in 2023, favored for its balance of efficacy and safety. It remains a standard dosage across hospitals and surgical centers. However, the 15 mg/mL segment is gaining traction, especially in geriatric and renal-compromised populations due to its lower risk profile.

Market by End-use Insights:

The Hospitals segment dominated the market in 2023, accounting for more than 55% of the revenue. High patient volume, availability of skilled professionals, and emergency care infrastructure support extensive usage of injectable pain relievers. The Ambulatory Surgical Centers (ASCs) segment is projected to grow at the fastest CAGR due to procedural convenience and reduced hospital stays.

Market by Regional Insights:

North America led the global ketorolac injection market in 2023, backed by high surgical rates, regulatory clarity, and strong healthcare infrastructure. Asia-Pacific is forecasted to exhibit the highest growth rate during 2023–2031 due to increasing healthcare spending, expanding surgical infrastructure, and growing pain management awareness in countries like India and China.

Competitive Scenario:

Leading players in the Global Ketorolac Injection Market include Pfizer Inc., Mylan N.V., Teva Pharmaceuticals, Hospira (a Pfizer company), Hikma Pharmaceuticals, Amneal Pharmaceuticals, and Apotex Inc. These companies are focusing on expanding their generics portfolio, developing new delivery mechanisms, and strengthening regional distribution.

Key Market Developments:

2023: Pfizer launched a prefilled ketorolac syringe for hospital emergency use in the U.S. market.

2024: Hikma Pharmaceuticals received regulatory approval for a generic version of ketorolac injection in the EU.

2025: Teva Pharmaceuticals expanded its pain management product line with combination therapies targeting post-operative pain relief.

Scope of Work – Global Ketorolac Injection Market

Report Metric Details

Market Size (2023) USD 445 million

Projected Market Size (2031) USD 679 million

CAGR (2023–2031) 5.4%

Market Segments By Formulation Type (15 mg/mL, 30 mg/mL), End-use (Hospitals, ASCs, Clinics), Region

Growth Drivers Increase in surgeries, shift to non-opioid pain management, aging population

Opportunities ASC demand, emerging markets, advanced formulations

FAQs:

1. What is the current market size of the Global Ketorolac Injection Market?

The market size was valued at USD 445 million in 2023.

2. What is the major growth driver of the Global Ketorolac Injection Market?

The shift towards non-opioid pain management and rising surgical volume are the primary growth drivers.

3. Which is the largest region during the forecast period in the Global Ketorolac Injection Market?

North America is expected to maintain its lead throughout the forecast period.

4. Which segment accounted for the largest market share in the Global Ketorolac Injection Market?

The Hospitals segment held the largest market share in 2023.

5. Who are the key market players in the Global Ketorolac Injection Market?

Key players include Pfizer Inc., Teva Pharmaceuticals, Mylan N.V., Hospira, and Hikma Pharmaceuticals.